Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

To join this study, you need to be at least 18 years old and have a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS), or a similar poorly differentiated sarcoma. It's important that your cancer has either spread to other parts of your body (metastatic) or cannot be removed through surgery (unresectable).

There are also some important rules about pregnancy and breastfeeding. You cannot take part if you are pregnant or breastfeeding, as the treatments could be harmful. If you are a woman who could become pregnant, you'll need to have a negative pregnancy test before starting the study. Both men and women taking part must agree to use effective birth control or avoid sexual activity during the study and for a period afterwards.

If you join this study, you would be randomly assigned to one of two treatment groups. In one group, you would receive the chemotherapy drug doxorubicin. In the other group, you would receive doxorubicin along with the immunotherapy drug pembrolizumab. Both drugs are given through a drip into your vein.

You would receive treatment cycles every 21 days. The doxorubicin would be given for up to 6 cycles. The pembrolizumab, if you're in that group, would continue for up to 2 years, as long as your cancer isn't getting worse and you're not experiencing severe side effects. You'd also have regular check-ups, scans (like diagnostic imaging), heart tests (like echocardiograms or MUGA scans), and blood tests to monitor your health and how the treatment is working. Some tissue samples might also be collected. The study doctors will carefully explain all the tests and visits involved.